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Adenoviral vectors have been used in gene therapy and for vaccination. The major concerns with using adenoviral vectors
are the pathogenic potential of the virus backbone and the generation of replication-competent adenovirus that may replicate
in an uncontrolled manner, especially in immunocompromised patients. It is important to develop new vectors that are safer
for clinical trials while maintaining high titer and efficient transduction. A new adenovirus vector production system was
developed, which includes several vector backbone plasmids deleted for E2a and a new cell line expressing both E1 and E2a.
The new cell line with the tTA-inducible E2a expression cassette can significantly increase the titer of E1/E2a-deleted vectors
by four to five orders of magnitude upon withdrawal of tetracycline. Furthermore, there is no sequence overlap between the
vector and the cellular DNA within the E2a open reading frame and downstream, making the generation of virus with wild-type
E2a through homologous recombination substantially less likely. The new vector system may improve the safety of vectors
for vaccination and cancer therapy and may also provide safer backbones for further vector development, such as
helper-dependent and hybrid vectors. © 2000 Academic PressINTRODUCTION
Human adenoviral (Ad) vectors are one of the more
efficient vehicles for transferring foreign genes into
mammalian cells for vaccination and for gene therapy of
cancer and hereditary diseases. Ad vectors have been
well characterized, are easy to manipulate, and can be
grown to high titers. One potential advantage of Ad
recombinant vaccines is their ability to elicit protective
cell-mediated immunity and humoral responses to the
antigen delivered by the vector (Randrianarison-Jew-
toukoff and Perricaudet, 1995). The vectors can also
induce mucosal immune responses that are particularly
important in AIDS vaccine development. For example, Ad
vectors carrying the HIV-1 gp120 gene or the simian
immunodeficiency virus pg120 gene resulted in high-titer
neutralizing antibodies and cellular and mucosal im-
mune responses; this provided long-term protection fol-
lowing AIDS virus challenge (Lubeck et al., 1997; Buge et
al., 1997). One additional application of Ad vectors is their
use in cancer gene therapy (Zhang, 1999). The ap-
proaches include induction of anticancer immunity
through the delivery of either immunomodulatory genes,
such as interleukin-12 (Davidoff et al., 1999), or the genes
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348of tumor-specific antigens, such as polyoma middle T
(Wan et al., 1999).
The major concern with using recombinant Ad vec-
tors is the pathogenic potential of the adenovirus
backbone. Most Ad vectors used in vaccines are E1-
substituted first-generation vectors (Randrianarison-
Jewtoukoff and Perricaudet, 1995; Zhang, 1999). The
E1-substituted vectors are usually produced in 293
cells generated by the transfection of human kidney
cells with sheared Ad serotype 5 (Ad5) DNA (Graham
et al., 1977). Mapping of the Ad sequences in the 293
cell line has indicated the presence of contiguous Ad5
sequences from the left-hand end of the genome up to
position 4137 (Louis et al., 1997). When typical E1-
substituted vectors, which contain a deletion of the E1
region from 340 to 3500 of the Ad genome, are prop-
agated in 293 cells, sequence overlap frequently re-
sults in the generation of replication-competent ade-
novirus (RCA) (Lochmuller et al., 1994; Hehir et al.,
1996; Fallaux et al., 1999). RCA has the potential to
replicate in an uncontrolled manner in patients, espe-
cially in immunocompromised individuals such as
AIDS or cancer patients. The presence of RCA in Ad
vector preparations for clinical use may cause com-
plications and is clearly undesirable. One approach to
prevent RCA is the development of cell lines lacking
overlapping sequences (Fallaux et al., 1998; Gao et al.,
2000).
The other concern with E1-subtituted Ad vectors is that
the vectors may still be able to replicate even with the
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349NEW VECTOR SYSTEM WITH INDUCIBLE E2a CELL LINEdeleted E1 region. Research has shown that virus with a
mutated E1 region did not completely eradicate the syn-
thesis of viral proteins and DNA (Winberg and Shenk,
1984; Shenk and Williams, 1984). The synthesis of the
viral DNA and proteins has been observed when E1-
deleted vectors were used to infect noncomplementing
cells (Mittereder et al., 1994). Host cellular factors may
provide the “E1-like” function for replication of E1-deleted
vectors (Imperiale et al., 1984). In addition, adenovirus
can replicate very well, even if extremely low levels of E1
are expressed (Hearing and Shenk, 1983; Hitt and Gra-
ham, 1990). The 293 cell line, containing a single copy of
the E1 region (Louis et al., 1997), can propagate Ad
vectors to titers of 10,000 or more per cell. This further
suggests that small amounts of E1 or E1-like factors
could be sufficient to allow plentiful amplification of Ad
vectors. Hence, Ad vectors with E1 deletion may cause
unpredictable outcomes in clinical trials. It is important
both to achieve optimal expression of the therapeutic
gene and to avoid uncontrolled synthesis of Ad vectors in
therapy. One strategy is to develop new vectors with
additional deletions of other essential viral genes. Re-
search demonstrated a long time ago that an adenovirus
with deletion of another gene (E2a) could replicate in
complementing cells (Klessig et al., 1984).
The so-called second-generation vectors with deleted
E1/E2 or E1/E4 have been developed and the vectors
can be propagated in cell lines that complement both E1
and E2 or E1 and E4 (Zhou et al., 1996; Gorziglia et al.,
996; Gao et al., 1996; Amalfitano et al., 1998; Lusky et al.,
998). Vectors with E1/E2 deletions cannot replicate in
oncomplementing cells and therefore may improve
afety in gene therapy (Zhou et al., 1996; Lusky et al.,
998; Gorziglia et al., 1996). However, the advantages of
he vectors with regard to extending transgene expres-
ion remain to be studied further (Amalfitano, 1999). The
1/E2-deleted vectors have resulted in immune re-
ponses similar to those elicited by the vectors with only
he E1 region deleted, as we have previously demon-
trated (Morral et al., 1997). This may limit the vector
pplication in gene therapy for hereditary diseases, but
hould be attractive for the development of viral recom-
inant vaccines. To further improve the E1/E2a-deleted
ector systems, we have developed several vector back-
one plasmids deleted for E2a open reading frame (ORF)
nd a new inducible E2a complementing cell line, E2T.
here is no sequence overlap between the vector and
he cellular DNA within the E2a ORF and downstream.
he titer of E1/E2a-deleted vector was significantly in-
reased in response to withdrawal of tetracycline and no
2a wild-type virus could be detected in the vector prep-
rations. Construction and preparation of the E1- and
2a-deleted vectors has been simplified. The new vector
ystem may be especially useful for vaccine and cancerherapy. cRESULTS
evelopment of inducible E2a-complementing cell
ines
Because high-level expression of the E2a product is
ssential for preparation of high-titer Ad vectors with
eletion of E2a, the tetracycline-regulated system (Gos-
en and Bujard, 1992; Resnitzky et al., 1994) was used for
evelopment of E2a-expressing inducible cell lines. This
ystem has two components. The transactivator protein
TA, encoded in plasmid pUHD15-1, is a fusion protein
omposed of the repressor of the tetracycline operon
tetR) from Escherichia coli (Tn 10) and the activating
omain of herpes simplex virus protein 16 (Gossen and
ujard, 1992). The PhCMV*-1 region, in the response
lasmid pUHD10-3, contains the CMV core promoter and
everal repeats of tet operator (tetO) sequences
Resnitzky et al., 1994). In this system, the tTA binds to the
etO and induces transcription from the PhCMV*-1 pro-
oter in the absence of tetracycline, but not in its pres-
nce. We modified the system for facilitation of develop-
ent of the E2a-complementing cell line. First, a selec-
ive marker neomycin-resistant gene was introduced into
he regulator plasmid pUDH15-1 at the unique XhoI site,
esulting in a new plasmid designated pBZ47 (Fig. 1).
econd, the CMV core promoter was deleted from the
hCMV*-1 region in plasmid pUHD10-3, but the tetO
equences were retained. The E2a ORF, with its endog-
nous early promoter (E-P) and late promoter (L-P)
loned from pFG140, was inserted into the modified
UHD10-3. In the final plasmid construct, pBZ40, the E2a
-P and L-P were linked to the tetO, so that the tTA
ransactivator could enhance the E2a expression (Fig. 1).
o sequences downstream from the stop codon of the
2a ORF were included in the construct.
After cotransfection with the pBZ40 and pBZ47 plas-
ids into 293 cells, over 100 G418-resistant colonies
ere selected. Only 1 of the colonies (293-G7) had effi-
ient inducible complementing ability upon withdrawal of
etracycline from the culture medium (Fig. 2). Unfortu-
ately, the inducible 293-G7 cell line did not produced a
igh titer of E2a-deleted vector even compared with the
revious noninducible 293-C2 cell line (Fig. 2) (Zhou et
l., 1996). We reasoned that introducing multiple copies
f the E2a-expressing cassette into 293-G7 cells could
ncrease the E2a-complementing ability. We did a sec-
nd cotransfection of the E2a-expressing plasmid pBZ40
nto 293-G7 cells with another selective plasmid, pPGK-
urobpA, containing a puromycin resistance cassette
provided by Dr. Allan Bradley). Two resistant colonies
293E2T-1 and 293E2T-11) that could significantly in-
rease the titer of the E2a-deleted vector in culture upon
ithdrawal of tetracycline were selected from puromy-
in-resistant clones.
To compare the titers of an E2a-deleted vector with aomparable vector containing a wild-type (WT) E2a re-
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350 ZHOU AND BEAUDETgion, we used our previously constructed AdbgalDE1E2
deleted E2a) and AdbgalDE1 (WT E2a) vectors (Zhou et
l., 1996) to infect 293 and different E2a-complementing
FIG. 1. Depiction of the DNA segments in plasmids used to develo
eletion of E2a. (A) The tTA gene and neomycin resistance cassette in p
ragment and tetracycline operator sites (tetO) is in the middle. Tran
promoters when tetracycline is absent. The addition of tetracycline inhi
bp 22445 to 24028 is shown. (B) The restriction enzyme sites used to
and adenoviral vectors are shown. The start and stop codons of E2
coordinates refer to Ad5 (GenBank Accession No. M73260).
FIG. 2. Comparison of the titers of viruses with wild-type E2a or with
deletion of E2a on 293 cells and E2a-complementing cells. Titer of the
virus with wild-type E2a, AdbgalDE1, is shown on the left, and titer of
he virus with E2a deletion, AdbgalDE1E2, is shown on the right.
Hatched bars indicate viruses produced in medium containing 10
mg/ml tetracycline, and solid bars indicate viruses produced in a
medium without tetracycline. Virus was collected from the medium
after 2 days of infection with an m.o.i. of 1, and the titer was measured
as blue forming units (BFU) on E2T cells. The titer of AdbgalDE1E2 in
293 cells is not higher than can be accounted for by the input virus,
because the E2a-deleted virus cannot replicate (Zhou et al., 1996).
AdbgalDE1E2 can replicate in uninduced E2T cells (with tet) with titersqsubstantially below those with induced E2T cells (without tet).ells at a multiplicity of infection (m.o.i.) of 1. The cells
ere cultured in medium with or without tetracycline.
fter 2 days of infection, the total cultures with cells were
ollected; lysates were prepared and serially diluted to
etermine the titers. The titers of the AdbgalDE1 con-
aining WT E2a were the same regardless of cell lines
nd tetracycline, because the AdbgalDE1 did not depend
on E2a complementation from cells. The titers of
AdbgalDE1E2 vector in noninducible 293-C2 cells (Zhou
t al., 1996) were relatively low compared to the E2a-WT
ector and there was no difference whether adding tet-
acycline in medium or not. However, 293E2T-1 and
93E2T-11 cells increased the titer of the E2a-deleted
ector four to five orders of magnitude upon withdrawal
f tetracycline in cultures, with the titer reaching levels
imilar to those of the E2a wild-type vector (Fig. 2). The
2a-deleted vector could not replicate in 293 cells.
ultiple copies of E2a in complementing cells
It was possible that the higher yield of the E2a-deleted
ector in the 293E2T-1 and 293E2T-11 cells, compared to
93-G7 cells, was due to multiple E2a cassettes in these
ells. To evaluate this, the copy number of the E2a gene
as determined by Southern hybridization. About 20 cop-
es of the E2a gene were present in both 293E2T-1 and
93E2T-11 cells, while there were only 1 or 2 copies in
93-G7 and 293-C2 cells (Fig. 3). Since there was no
ifference between the 293E2T-1 and the 293E2T-11 cell
ines, we focused on the 293E2T-1 (E2T) cells in subse-
nducible E2a-complementing cell lines and to construct vectors with
pBZ47 are shown at the top. Plasmid pBZ40 containing the adenoviral
tor protein tTA interacts with tetO, enhancing transcription from E2a
nscription. The structure of plasmids and vectors deleted for E2a from
he E2a ORF and the sequences around the deleted sites in plasmids
are depicted. All of the map units (mu) and nucleotide sequencep the i
lasmid
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351NEW VECTOR SYSTEM WITH INDUCIBLE E2a CELL LINEE2a protein induced in the E2T cell upon withdrawal
of tetracycline
Expression of E2a was analyzed by Western blotting.
As a positive control, 293 cells were infected with the
E2a WT vector AdFG140; as a negative control, 293 cells
were infected with an E2a-deleted vector AdFG140DE2.
E2T cells were grown in medium with or without tetra-
cycline. Cell lysates were isolated from these cells for
Western blotting. As expected, 293 cells infected with the
E2a WT vector had a high level of E2a expression from
the vector, in contrast to undetectable E2a in 293 cells
infected with the E2a-deleted vector. The level of the E2a
gene product in E2T cells cultured in medium without
tetracycline was about threefold higher than that from
the same cells cultured in medium containing tetracy-
cline (Fig. 4). This provides direct evidence that the
transcriptional activity of the E2a endogenous promoters
in the E2T cells was enhanced by the tetracycline sys-
tem. In the noninduced condition (with tetracycline), the
protein was still produced from the cell because of the
basal activity of the endogenous E2a promoters. To test
whether infection of E2a-deleted adenovirus would in-
hibit expression of E2a in the complementing cells, we
infected the E2T cells with AdFG140DE2. The results
showed that infection with the E2a-deleted vector did not
inhibit expression of E2a in the E2T cells under both
induced and noninduced conditions (Fig. 4).
Inducing the titer of E2a-deleted adenovirus with
tetracycline
E2T cells were grown under the same conditions as
293 cells, except for the addition of 10 mg tetracycline/ml
to keep the E2a expression at relatively lower levels.
There was no detectable difference between E2T and
293 in growth characteristics and morphologies after the
E2T cell cultured for several years and over at least 20
passages (Fig. 5). When E2T cells were infected with
AdbgalDE1E2 at an m.o.i. of 0.1, complete CPE was only
bserved in 2 days in the E2T culture without tetracy-
FIG. 3. Southern blot analysis of the E2a copy number in C2, G7
293E2T-1, and 293E2T-11 genomic DNA. The probe was a 1.75-kb PCR
product amplified from the E2a coding region of AdFG140 DNA with
primers of 731 and 732 (Fig. 7). Standard lanes contain 1 to 25 copies
of viral E2a, each mixed with 10 mg of 293 genomic DNA. The DNA
amples were cleaved with restriction endonucleases EcoRI and DraI.line, while partial CPE was observed in the culture withetracycline. The E2a-deleted vector did not cause 293
PE (Fig. 5).
The E2a-deleted AdbgalDE1E2 was also used to infect
2T cells cultured in medium with various concentra-
ions of tetracycline. The titer of the vector produced in
ell culture was induced from about 105 to 109 blue
forming units (BFU)/ml, while the tetracycline concentra-
tion was decreased from 10 to 0 mg/ml. The production of
the E2a-deleted vector was inhibited at levels as low as
0.1 mg/ml of tetracycline (Fig. 6). The above experiments
indicated that decreasing concentrations of tetracycline
in medium resulted in higher yields of E2a-deleted vec-
tor.
Development of adenoviral vectors with deletion of
the entire of E2a ORF
To substantially reduce the possibility of homologous
recombination in the E2a sequence between the E2T
cells and the vectors, we deleted a segment of 1584 bp
covering the entire E2a ORF from Ad genomic plasmids
pFG140, pBHG10, and pBHE3 to generate plasmids
pBZ66, pBZ68, and pBZ71, respectively (Fig. 1 and Table
1). Multiple restriction sites (PacI–XbaI–BstB1–ClaI) were
introduced into the deleted region to allow cloning trans-
genes in the deleted E2a region. With the previously
established method for generating first-generation Ad
vectors (Bett et al., 1994), the E2a-deleted plasmid pBZ66
ould be directly converted into an E2a-deleted Ad vector
AdBZ66DE2) in the E1- and E2a-complementing E2T
ells (Table 1). Plasmids pBZ68 and pBZ71 have been
sed to rescue second-generation vectors with multiple
eletions of E1/E2a/E3 or E1/E2a (data not shown). All of
hese plasmids and Ad vectors were documented to
ontain the appropriate deletions as exemplified in Fig. 7
y PCR analysis of AdBZ66DE2. The deletion of the E2a
FIG. 4. Western analysis of E2a protein produced in E2T cells. The
E2a gene product DBP was detected by Western blot as described
under Materials and Methods. DBP was seen in 293 cells infected by
AdFG140 with wild-type E2a, but not in 293 cells infected with E2a-
deleted AdFG140DE2. E2T cells expressed increased levels of DBP
when tetracycline was omitted from the medium.
or wit
352 ZHOU AND BEAUDETgene in these vectors was confirmed by restriction en-
zyme analysis with HindIII, AscI, and EcoRI–BamHI (data
not shown).
FIG. 5. Comparison of 293 cells and E2T cells with regard to morph
with E2a-deleted vector at an m.o.i. of 0.1 without tetracycline (middle)
FIG. 6. Growth of E2a-deleted vector in E2T cells with different
concentrations of tetracycline in medium. AdbgalDE1E2 was used to
infect E2T cells cultured in medium with different concentrations of
tetracycline. The vector titer increased with decreasing concentrations
of tetracycline.Absence of detectable E2a wild-type virus from
preparations of second-generation Ad vectors
To test whether E2a WT virus would emerge during
amplification of the E2a-deleted vectors in E2T cells, we
successively infected E2T cells with the AdBZ66DE2
virus. After a total of 20 serial passages, the virus was
assayed for WT E2a. AdBZ66DE2 was compared with
AdFG140 containing a WT E2a region prepared from 293
cells and AdFG140DE2 containing partially deleted E2a
prepared from the previous E2a-complementing 293-C2
cells (Zhou et al., 1996). PCR with a pair of primers, one
(551) located within the deleted E2a ORF and another
(731) located outside of the ORF, was specifically used to
assess the presence of the WT E2a sequence. With
primers 551 and 731, a fragment of about 0.68 kb repre-
senting the WT E2a PCR product was amplified from
E2a-WT AdFG140. For the E2a partial-deleted
AdFG140DE2 which contains overlapping sequences
with the complementing 293-C2 cells, there was a weak
band of a 0.68-kb fragment when primers 551 and 731
were used (Fig. 7). This suggested the emergence of E2a
WT virus from AdFG140DE2 vector propagated in 293-C2
cells. However, this 0.68-kb fragment could not be de-
tected for AdBZ66DE2 propagated in the new E2T cells
(Fig. 7). Primers 731 and 732 flanking the E2a ORF
yielded a 1.75-kb fragment for AdFG140 and shortened
fragments for AdFG140DE2 and AdBZ66DE2 (Fig. 7). PCR
with primers of 731 and 732 did not yield the WT 1.75-kb
fragment for AdFG140DE2, because when there was only
a small amount of WT E2a viruses, the primers favor
nd CPE. The 293 cells and E2T cells were uninfected (left) or infected
h tetracycline (right) in medium.ology aamplification of the shorter (0.48-kb) fragment. In the past
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product for AdBZ66DE2 (deleted entire E2a).
353NEW VECTOR SYSTEM WITH INDUCIBLE E2a CELL LINEfew years we have used E2T cells to make multiple
preparations of E2a-deleted vectors. No evidence of con-
tamination with WT E2a was found in any of these prep-
arations (O’Neal et al., 1998).
DISCUSSION
The E1-substituted first-generation Ad vectors have
een used in gene therapy and vaccination (Randrianari-
on-Jewtoukoff and Perricaudet, 1995; Zhang, 1999).
owever, the potential pathogenicity of Ad vectors re-
uires particular attention, especially in infants and in
IDS and cancer patients who are candidates for vac-
ine treatment. Emergence of RCA in final batches of
1-substituted vectors and possible preexisting E1-like
actors in some host cells may cause uncontrolled
denoviral replication in humans. Ad vectors with addi-
ional deletions in other critical viral genes may benefit
d-mediated vaccination and gene therapy. The DNA-
inding protein (DBP) encoded by the Ad E2a gene is
ssential for viral DNA replication and for transcription
rom the major late promoter that controls the synthesis
f all viral structural proteins (Shenk, 1996). Previous
tudies confirmed that, unlike the first-generation vec-
ors, vectors with deletions in E1 and E2a do not express
etectable adenovirus early and late proteins and do not
ynthesize viral DNA in noncomplementing cells (Gor-
iglia et al., 1996; Christ et al., 1997; Rittner et al., 1997;
Lusky et al., 1998). Vectors with deletions of both E1 and
E2a can efficiently deliver foreign genes into animals, but
al Vectors
Reference
Graham, 1984
Bett et al., 1994
3 Bett et al., 1994
Bett et al., 1994
pression system Resnitzky et al., 1994
Gossen and Bujard, 1992
ed from pUHD10-3 This report
derived from pUHD15-1 This report
This report
This report
This report
of AAV, derived from This report
tte Provided by A. Bradley
a Zhou et al., 1996
deleted Zhou et al., 1996
Zhou et al., 1996
Zhou et al., 1996
This reportTABLE 1
Plasmids and Vir
Plasmid or vector Description
Plasmids
pFG140 Insertion of 2.21 kb in E1; dl309 in E3
pBHGE3 Deletion of packaging signal and E1
pBHG10 Deletion of packaging signal, E1, and E
pDE1sp1A Shuttle for adenovirus vector
pUHD10-3 Response plasmid in tTA-dependent ex
pUHD15-1 Contains transactivator protein tTA
pBZ40 Inducible E2a-expressing plasmid, deriv
pBZ47 Contains protein tTA and Neo-resistant,
pBZ66 pFG140DE2a-ORF
pBZ68 pBHG10DE2a-ORF
pBZ71 pBHGE3DE2a-ORF
pBZ92 Shuttle containing b-gal flanked with ITR
pDE1sp1A
pPGKpurobpA Contains a puromycin resistance casse
Viral vectors
AdbgalDE1 b-Gal-expressing vector with E1 deleted
AdbgalDE1E2 b-Gal-expressing vector with E1 and E2
AdFG140 Vector derived from pFG140
AdFG140DE2 Vector derived from pFG140DE2
AdBZ66DE2 Vector derived from pBZ66
aFIG. 7. PCR analysis of the deleted E2a region in adenoviral vectors.
(A) Primers within and flanking the E2a ORF are indicated at the top. (B)
Primers flanking the E2a ORF yielded full-length segments for
AdFG140, which contains wild-type E2a, while the appropriate smaller
products were seen for the vectors with partial or completely deleted
E2a ORF. The primer within the E2a ORF yielded a 0.68-kb fragment for
AdFG140 and AdFG140DE2 (partial deletion), but did not yield any PCRthese vectors still elicited immune responses against the
354 ZHOU AND BEAUDETtransgene protein as did first-generation vectors (Zhou et
al., 1996; Morral et al., 1997). Hence the E1/E2a-deleted
vectors may have limited application in gene therapy for
hereditary disease, but should be attractive for recombi-
nant viral vaccines.
Using the previously described E1/E2a-deleted vector
system, construction and preparation of the E1/E2a-de-
leted vector was complicated compared to the first-gen-
eration Ad vectors. The titer of E2a-deleted vectors was
generally lower than that of the vectors with the E2a
region intact, and there still was the possibility of the
emergence of RCA due to the overlapping sequence in
the E2a region between the vectors and the cell line.
These factors have hindered the use of E2a-deleted
vectors for vaccine applications in human clinical trials.
To increase the titer of E2a-deleted vector, we applied
the tTA-inducible system to enhance E2a promoter ac-
tivity in complementing cells. When E2T cells are cul-
tured in medium containing tetracycline, the E2a expres-
sion is under the control of its endogenous promoters.
Removing tetracycline from the medium increased E2a
protein by threefold in the cells (Figs. 1 and 4). An
important feature of the new cell line is that withdrawal of
tetracycline from the medium can significantly increase
the titer of E2a-deleted vector by four to five orders of
magnitude (Figs. 2 and 6). It is not certain how a few-fold
increase of E2a product results in a four to five orders of
magnitude increase of the vector titer. Although adeno-
virus replication is directly dependent on the E2a prod-
uct, this may not necessarily be a linear relationship.
Under the induced condition, the E2a product in E2T
cells increased to a level similar to that of 293 cells
infected with the E2a WT vector (Fig. 4); this may be
adequate for maximal virus production. Since high levels
of E2a may be toxic to cells, we generally add tetracy-
cline (final concentration, 10 mg/ml) in the maintenance
cultures. Under this condition, the cell line is quite stable
over the years even if the E2a is still expressed from its
endogenous promoters. The E2T cells did not have any
detectable morphological changes compared with 293
cells under the microscope (Fig. 5).
In this vector system, there are no homologous se-
quences between the vector DNA and the cellular DNA
in the region immediately downstream of the E2a ORF.
The E2a promoter region does exist in the E2T cell line
and overlaps with the vectors (Fig. 1). However, with
sequence overlap only at one end of the E2a ORF, there
is a substantially reduced potential for a double-cross-
over event necessary for the generation of an E2a wild-
type virus or vector. The vector system will provide a
relatively safer gene delivery method for gene therapy
and vaccination. This system reported here is based on
the 293 cell line. Therefore, the possibility of generating
E1 WT virus with an E2a deletion still exists. A further
improvement of this system would be to develop cell
lines that do not contain homologous sequences in theE1 region as in PER.C6 (Fallaux et al., 1998) and GH329
(Gao et al., 2000).
First-generation Ad vectors with E1 and E3 deletions
can accommodate up to 8 kb of inserted DNA (Bett et al.,
1994). With the added deletion of 1.6 kb in the E2a ORF,
the packaging capacity of Ad vectors increases to about
10 kb. The added capacity for an E1/E2a/E3-deleted Ad
vector will permit the delivery of larger or multiple foreign
genes or the delivery of complex inducible sequences,
such as the tTA or RU486 (Wang et al., 1994) systems, to
regulate foreign gene expression. Another direction for
vector development is to construct hybrid vectors, such
as Ad-adeno-associated virus and Ad-retrovirus vectors,
which may combine advantages from two different vi-
ruses. Our E2a-deleted vectors will not only expand the
capacity, but also provide a safer backbone for such
construction.
Recently developed helper-dependent (HD) Ad vectors
can significantly decrease toxicity and immune re-
sponses and prolong transgene expression (Haecker et
al., 1996; Schiedner et al., 1998; Morral et al., 1998, 1999).
In the HD-Ad vector system, a modified first-generation
Ad vector is used as a helper virus. Since multiple coin-
fections of the helper virus and the HD-Ad vector are
necessary to produce the HD-Ad vector, the contamina-
tion of helper virus in the HD-Ad vector preparations
cannot be avoided with the current 293Cre cell lines. In
addition, there is substantial possibility for the occur-
rence of RCA in the HD-Ad vector preparations (Parks et
al., 1996). Based on the E1/E2a-deleted vector system
reported here, the E1/E2a-complementing cell line and
the E1/E2a double-deleted vector have been modified for
preparation of the HD-Ad vectors that may further im-
prove the safety of the HD-Ad vector system (H. Zhou and
A. L. Beaudet, unpublished results).
Overall, the system reported here increased the titer of
vectors with E1 and E2a deletion and decreased the
potential for generating replication-competent adenovi-
rus. Since the E2a gene is essential for adenovirus DNA
replication and protein synthesis, we believe that vectors
deleted for both E1 and E2a will significantly improve
safety when used to prepare vaccines for infectious
diseases and cancer. The E1/E2a-deleted vector may
also provide a safe backbone for further Ad vector de-
velopment. In addition, the E2a-inducible cell lines and
the E2a-deleted viruses would be useful for the study of
DNA replication and virus propagation.
MATERIALS AND METHODS
Plasmids and viral vectors
Brief descriptions and references for plasmids and
viral vectors are provided in Table 1. The pFG140 (Gra-
ham, 1984), pBHGE3, and pBHG10 plasmids (Bett et al.,
1994) contain adenovirus genomic DNA in plasmid
forms. Plasmid pFG140 contains a small insertion of
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355NEW VECTOR SYSTEM WITH INDUCIBLE E2a CELL LINEbacterial DNA sequences in the E1 region of the Ad5
genome and is infectious in E1-complementing 293 cells.
The pBHE3 and pBHG10 plasmids have a deletion of part
of the E1 region, including the essential viral packaging
signal. Plasmid pBHG10 also carries a deletion in the E3
region, while pBHGE3 is wild type for E3. Plasmid
pDE1spA1 is an adenovirus shuttle plasmid (Bett et al.,
1994). Homologous recombination of the shuttle plasmid
or its derivative constructs with one of the adenovirus
genomic plasmids, pBHGE3 and pBHG10, would result in
the presence of infectious vector in complementing cells.
The above adenovirus plasmids were kindly provided by
Dr. F. Graham. Plasmid pUHD15-1 (Gossen and Bujard,
1992) and pUHD10-3 (Resnitzky et al., 1994) are regulator
and response plasmids, respectively, in the tTA-depen-
dent expression system and were kindly provided by Dr.
H. Bujard. Adenovirus vectors AdFG140, AdFG140DE2,
and AdbgalDE1E2 were constructed by the authors and
eported previously (Zhou et al., 1996). Other plasmids
nd vectors constructed in this report are also listed in
able 1 and are described elsewhere in this paper.
onstruction of E2a expression cassette and cell
ines
Plasmid pUHD10-3 was first modified by cleaving its
MV core promoter with the restriction enzymes SmaI
nd BamHI and then inserting a polylinker (SmaI–EcoRI–
baI–PmeI–BamHI, annealing of 59-GGGAATTCTCTA-
AGTTTAAACG and 59-GATCCGTTTAAACTCTAGAGAAT-
CCC) in the deleted site. An adenovirus fragment con-
aining the E2a ORF with its own promoters was cleaved
rom the plasmid pFG140 with EcoRI and DraI and cloned
into the polylinker at EcoRI and PmeI, resulting in plas-
mid pBZ40 (Fig. 1). DraI digestion destroyed the stop
codon for E2a ORF, but blunt-end ligation of PmeI-end
59-GTTT and DraI-end AAA-39 regenerated the stop
codon (59-GTTT/AAA-39). In the final construction of
pBZ40, the E2 promoters are directly linked to the tet
operators, and the E2a ORF was connected with the
SV40 poly A site (Table 1 and Fig. 1). To facilitate selec-
tion of E2a-complementing cells, a neomycin resistance
cassette excised with XhoI from pol2sneobpA (Soriano et
l., 1991) was inserted into pUHD15-1, resulting in pBZ47
Table 1 and Fig. 1). Plasmids pBZ40 and pBZ47 were
ransfected into 293 cells by calcium phosphate precip-
tation (Graham, 1991). Two days after transfection, the
ells were selected with 250 mg/ml G418. One of the
neomycin resistance colonies (293-G7) with inducible
E2a complementation was used for secondary transfec-
tion with pBZ40 and pPGKpurobpA (kindly provided by
Dr. A. Bradley) to increase E2a copies in the cells. The
cells were then selected with 1 mg/ml of puromycin. All
ells were grown in MEMa (Gibco, Grand Island, NY)
supplemented with 10% fetal bovine serum (Hyclone,
Logan, UT) and 100 U of penicillin and 100 mg of strep- tomycin per milliliter. E2T cells were maintained in the
bove medium containing 10 mg/ml of tetracycline to
aintain E2a expression at lower levels.
onstruction of plasmids and adenoviruses with
eletion of E2a ORF
To prepare vectors defective for E1 and E2a, a seg-
ent of 1584 bp (from Ad 22445 to 24028, GenBank
ccession No. M73260) covering the entire E2a ORF was
irst removed from a subclone of Ad sequences by using
raI and MscI restriction enzymes. MscI cleaved at 1 bp
ownstream of the start codon and DraI cut 1 bp into the
top codon for E2a ORF (Fig. 1B). The deletion removed
ll codons for the 529-amino-acid ORF for the E2a gene
xcept the start codon. The deletion was introduced into
FG140, pBHG10, and pBHGE3 by multiple steps as
escribed (Zhou et al., 1996) and resulted in pBZ66,
BZ68, and pBZ71, respectively (Table 1). Multiple restric-
ion sites (PacI–XbaI–BstB1–ClaI) were substituted at the
ite of the deleted E2a ORF.
Development of viral vectors from the adenoviral
enomic plasmids involved transfection of adenoviral
lasmids into complementing cells according to meth-
ds used for the construction of first-generation Ad vec-
ors (Graham, 1991). AdBZ66DE2 was converted from
lasmid pBZ66 after transfection into E2T cells.
ector purification, titer, and structure determinations
Plaque purification and titer determination were per-
ormed in six-well plates as described previously (Gra-
am, 1991; Zhou et al., 1996) with 293 or E2T cells.
Plaques appeared about 5 to 7 days after infection of the
vectors.
Two pairs of PCR primers were used for identification
of E2a-deleted virus. One pair of PCR primers, 731 (59-
AGTGCGCAGATTAGGAGCGC) and 732 (59-GCCTATAG-
GAGAAGGAAATG), flanking the E2a ORF, was used to
analyze the WT E2a. Primer 551 (59-CCGGCAAGTCTT-
GCGGCATG) located inside of the E2a ORF was used
with primer 731 for detection of contamination with the
WT E2a. PCR reaction conditions were 94°C for 2 min
and then 30 cycles of 30 s at 94°C, 30 s at 55°C, and 1
min at 72°C.
The copy number of E2a gene was assayed by South-
ern hybridization of genomic DNAs cleaved with restric-
tion enzymes, EcoRI and DraI, cutting out the cloned E2a
sequences. The control standards for copy number were
prepared by adding 1, 2, or multiple microliters of 1.33 3
1025 mg/ml of pBZ40 into 10 mg of 293 genomic DNA,
quivalent to 1, 2, or multiple copies of E2a per cell.
estern blotting for E2a protein DBP
The treated cells were scraped off and washed in 4°C
hosphate-buffered saline containing 5 mM EDTA andhe cell pellet was lysed. The soluble protein in the
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356 ZHOU AND BEAUDETlysates was collected from the supernatant after centrif-
ugation at 15,000g for 30 min at 4°C. After being boiled,
10-mg samples were separated on a sodium dodecyl
ulfate–7.5% polyacrylamide gel and then electrophoreti-
ally transferred to a 0.45-mM nitrocellulose membrane
Bio-Rad). The membrane was washed in blocking buffer
nd incubated with rabbit antibody against DBP (Voelk-
rding and Klessig, 1986) diluted 1:2000, followed by
reatment with a second antibody (horseradish peroxi-
ase-linked anti-rabbit immunoglobulin from donkey;
mersham, Arlington, IL) diluted 1:2000. The probed DBP
as detected with an enhanced chemiluminescence
ystem (Amersham, Arlington, IL) according to the man-
facturer’s instructions.
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